Solid State Pharma Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$520K
- Investors
-
5
Solid State Pharma General Information
Description
Provider of crystallization engineering services intended to understand the solid state of drug candidate's products. The company's services include screening and selection of polymorphs, co-crystals, salts, and crystallization process development and optimization, enabling pharmaceutical companies to improve bioavailability and decrease the oral daily dose to lower side effects.
Contact Information
Website
www.solidstatepharma.comCorporate Office
- 1489 Hollis Street
- Suite 300
- Halifax, Nova Scotia B3J 3M5
- Canada
Corporate Office
- 1489 Hollis Street
- Suite 300
- Halifax, Nova Scotia B3J 3M5
- Canada
Solid State Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 21-May-2019 | $520K | Completed | Generating Revenue | ||
| 4. Grant | 01-Jan-2016 | Completed | Generating Revenue | |||
| 3. Grant | 15-Sep-2014 | Completed | Startup | |||
| 2. Early Stage VC | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Solid State Pharma Patents
Solid State Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210147433-A1 | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | Active | 12-Apr-2019 | ||
| US-12060354-B2 | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | Active | 12-Apr-2019 | ||
| US-20210122740-A1 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile | Inactive | 02-Jul-2018 | ||
| US-20220220093-A1 | Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | Pending | 22-Nov-2017 | ||
| US-11254652-B2 | Crystalline forms of n-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | Active | 22-Nov-2017 | C07D215/36 |
Solid State Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Solid State Pharma Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Government of Canada | Government | |||
| NSBI Venture Capital | Corporate Venture Capital | |||
| Atlantic Canada Opportunities Agency | Government | |||
| Invest Nova Scotia | Venture Capital | Minority | ||
| Life Sciences Nova Scotia | Accelerator/Incubator | Minority |
Solid State Pharma FAQs
-
When was Solid State Pharma founded?
Solid State Pharma was founded in 2014.
-
Where is Solid State Pharma headquartered?
Solid State Pharma is headquartered in Halifax, Canada.
-
What is the size of Solid State Pharma?
Solid State Pharma has 31 total employees.
-
What industry is Solid State Pharma in?
Solid State Pharma’s primary industry is Other Commercial Services.
-
Is Solid State Pharma a private or public company?
Solid State Pharma is a Private company.
-
What is Solid State Pharma’s current revenue?
The current revenue for Solid State Pharma is .
-
Who are Solid State Pharma’s investors?
Government of Canada, NSBI Venture Capital, Atlantic Canada Opportunities Agency, Invest Nova Scotia, and Life Sciences Nova Scotia have invested in Solid State Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
